早期生物制剂治疗克罗恩病的疗效与安全性:系统综述与荟萃分析
结果显示早期治疗与更高的临床缓解率、更低的复发率和更高的黏膜愈合率相关。
要点
- 早期生物制剂治疗与临床缓解率提高相关(OR 2.10)。
- 早期治疗与复发率降低相关(OR 0.31)。
- 早期治疗与黏膜愈合率提高相关(OR 2.37)。
核心结论
- 早期生物制剂治疗与成人和儿童克罗恩病患者临床结局改善相关,不仅见于前瞻性临床试验,也见于真实世界研究。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed和Embase至2019年4月30日的英文文献和会议摘要。
- 纳入标准为患者在克罗恩病诊断后2年内开始生物制剂治疗,或比较早期生物制剂(降阶梯)与常规升阶梯策略的研究。
关键数值与推荐
- 早期生物制剂治疗定义为病程<2年或降阶梯治疗策略;晚期/常规治疗定义为病程>2年或常规升阶梯策略。
临床怎么用
- 在克罗恩病病程早期(诊断后2年内)考虑使用生物制剂可能改善临床缓解、降低复发并促进黏膜愈合。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is an increasing body of evidence showing that earlier use of biologics improves clinical outcomes in Crohn's disease (CD). AIM: To perform a systematic review and meta-analysis to assess the impact of early biologic use in the treatment of CD. METHODS: PubMed and Embase databases were searched for English language papers and conference abstracts published through April 30, 2019. Studies were selected for inclusion if patients initiated biologics within 2 years of a CD diagnosis or if earlier biologics use (top-down) was compared with a conventional step-up strategy. Random-effects meta-analyses were conducted to compare clinical remission (CR), relapse and endoscopic healing rates between early biologic treatment (<2 years of disease duration or top-down treatment strategy) and late/conventional treatment (biologic use after >2 years of disease duration or conventional step-up treatment strategy). RESULTS: A total of 3069 records were identified, of which 47 references met the selection criteria for systematic review. A total of 18 471 patients were studied, with a median follow-up of 64 weeks (range 10-416). Meta-analysis found that early use of biologics was associated with higher rates of clinical remission (OR 2.10 [95% CI: 1.69-2.60], n = 2763, P < .00001), lower relapse rates (OR 0.31 [95% CI: 0.14-0.68], n = 596, P = .003) and higher mucosal healing rates (OR 2.37 [95% CI: 1.78-3.16], n = 994, P < .00001) compared with late/conventional management. CONCLUSIONS: Early biologic treatment is associated with improved clinical outcomes in both adult and paediatric CD patients, not only in prospective clinical trials but also in real-world settings.
引用
- Ungaro RC, Aggarwal S, Topaloglu O, et al. Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease. Aliment Pharmacol Ther. 2020. PMID: 32202328. doi:10.1111/apt.15685
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。